Breaking barriers in biologics manufacturing: EnzeneX™ to EnzeneX™ 2.0

Your guide to understanding Fully-Connected Continuous Manufacturing™ (FCCM™) that is transforming biologics manufacturing

In her latest interview with Pharmaceutical Technology Europe, Shilpa Gadgil, PhD shares valuable insights into our journey of innovation in biologics manufacturing: Breaking barriers with EnzeneX™ to EnzeneX™ 2.0

Here’s what she covers:
✔️The unique features of our Fully-Connected Continuous Manufacturing™ (FCCM™) platform
✔️How EnzeneX™ 2.0 builds on the original platform with groundbreaking advancements.
✔️The cutting-edge capabilities of our New Jersey site
✔️Success stories of large molecules we’ve produced using FCCM™
✔️Challenges we’ve tackled in tech transfer and scale-up—and how we overcame them

Take a closer look at how we’re transforming biologics manufacturing enabling access to affordable healthcare.

In the conversation, he delves into:
◉ The innovations driving EnzeneX™ 2.0.
◉ The challenges and successes in building this cutting-edge platform for biologics manufacturing.
◉ Our approach to sustainability and addressing global challenges.
◉ Scaling innovation to our New Jersey facility.